Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases

Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14.

Abstract

Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein we report two patient cases with mesothelioma who received second-line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin. The combination showed promising activity in both cases with manageable toxicity. We discuss the results of this regime in the light of historical as well as emerging data in mesothelioma.

Keywords: Lurbinectedin; Mesothelioma; Palliative chemotherapy.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carbolines / administration & dosage
  • Carbolines / adverse effects
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Clinical Trials, Phase I as Topic
  • Combined Modality Therapy
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / surgery
  • Male
  • Mesothelioma / drug therapy*
  • Mesothelioma / radiotherapy
  • Mesothelioma / surgery
  • Palliative Care / methods*
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / radiotherapy
  • Pleural Neoplasms / surgery
  • Prognosis

Substances

  • Carbolines
  • Heterocyclic Compounds, 4 or More Rings
  • PM 01183
  • Cisplatin

Supplementary concepts

  • Mesothelioma, Malignant